Core Insights - Fangzhou Inc.'s "XingShi" Large Language Model (XS LLM) is recognized as one of the most anticipated healthcare AI models in China for 2026, according to VBData [1] - XS LLM integrates five intelligent agents into a closed-loop system for chronic disease management, attracting international attention [2] - The model is built on over 1.1 million articles from 170 core journals, providing significant clinical support with nearly 400,000 instances of assistance to physicians [3] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, with 52.8 million registered users and 229,000 physicians as of June 30, 2025 [9] - The company specializes in AI-enabled precision medicine solutions and aims to deepen AI integration in chronic disease services [7] Product Features - XS LLM powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search, addressing various clinical and patient-side use cases [4] - Each application facilitates real-time interventions in medication guidance, patient education, diagnostic assistance, and medical reference [4] Industry Context - Other notable AI models in the market include those from JD Health, Ant Group, and Tencent Health, which are increasingly optimized for China's clinical guidelines and regulatory requirements [6] - The industry is working towards ambitious national targets for the development of medical AI models by 2027 and aims for near-universal intelligent clinical assistance in primary care by 2030 [6]
Fangzhou ’XingShi’ Large Language Model Highlighted Among China’s Most Anticipated Healthcare Models for 2026